India Globalization Capital Inc. (NYSEAMERICAN: IGC) jumped 11.49% after the company announced the completion of Cohort 3 of phase 1 clinical study on its tetrahydrocannabinol (THC)-based experimental new drug, IGC-ADI, for alleviating Alzheimer’s disease symptoms. FDA had approved IGC-ADI for Phase 1 study The company previously disclosed that it had […]